Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

Resumé

Development of resistance towards conventional antibiotics has become a huge problem worldwide. Infections which used to be easily treatable are now difficult to treat due to development of resistance. Therefore, we must turn to other approaches such as use of helper compounds. Helper compounds usually have no antibacterial properties themselves, however, when combined with antibiotics they are able to potentiate the effect of the antibiotic.
In our group, we are searching for novel helper compounds to be used in combination with antibiotics to fight resistant bacteria.
A potential helper compound is the cannabinoid cannabidiol (CBD) (Patent No. 17176612.4 - 1466). In our study, we have found through growth experiments that it is able to potentiate the effect of bacitracin against Methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria such as Listeria monocytogenes and Enterococcus faecalis.
Currently, we are working to clarify the mechanism of action of CBD and how it potentiates the effect of bacitracin. Therefore, various molecular experiments have been conducted such as RNA-sequencing of treated bacteria and whole-genome sequencing of CBD resistant strains. These results have led to several interesting genes selected for further studies. In addition, treatment with CBD have also shown to disrupt the membrane potential leading us to look further into how CBD affects the bacterial membrane. Therefore, we are currently looking on how CBD affects membrane fatty acid composition, fluidity and surface charge.
In conclusion, CBD is able to potentiate the effect of bacitracin towards MRSA, however, the mechanism of action still remains unknown.
OriginalsprogDansk
Publikationsdato2018
StatusUdgivet - 2018
Begivenhed18th International Symposium on Staphylococci and Staphylococcal infections - Mærsk Tower, Panuminstituttet, København, Danmark
Varighed: 23. aug. 201826. aug. 2018
Konferencens nummer: 18
http://isssi2018.org/

Konference

Konference18th International Symposium on Staphylococci and Staphylococcal infections
Nummer18
LokationMærsk Tower, Panuminstituttet
LandDanmark
ByKøbenhavn
Periode23/08/201826/08/2018
Internetadresse

Citer dette

Wassmann, C. S., & Klitgaard, J. K. (2018). Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues. Abstract fra 18th International Symposium on Staphylococci and Staphylococcal infections, København, Danmark.
Wassmann, Claes Søndergaard ; Klitgaard, Janne Kudsk. / Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues. Abstract fra 18th International Symposium on Staphylococci and Staphylococcal infections, København, Danmark.
@conference{b155c9022945454c91ba270a1486c9db,
title = "Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues",
abstract = "Development of resistance towards conventional antibiotics has become a huge problem worldwide. Infections which used to be easily treatable are now difficult to treat due to development of resistance. Therefore, we must turn to other approaches such as use of helper compounds. Helper compounds usually have no antibacterial properties themselves, however, when combined with antibiotics they are able to potentiate the effect of the antibiotic. In our group, we are searching for novel helper compounds to be used in combination with antibiotics to fight resistant bacteria.A potential helper compound is the cannabinoid cannabidiol (CBD) (Patent No. 17176612.4 - 1466). In our study, we have found through growth experiments that it is able to potentiate the effect of bacitracin against Methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria such as Listeria monocytogenes and Enterococcus faecalis. Currently, we are working to clarify the mechanism of action of CBD and how it potentiates the effect of bacitracin. Therefore, various molecular experiments have been conducted such as RNA-sequencing of treated bacteria and whole-genome sequencing of CBD resistant strains. These results have led to several interesting genes selected for further studies. In addition, treatment with CBD have also shown to disrupt the membrane potential leading us to look further into how CBD affects the bacterial membrane. Therefore, we are currently looking on how CBD affects membrane fatty acid composition, fluidity and surface charge. In conclusion, CBD is able to potentiate the effect of bacitracin towards MRSA, however, the mechanism of action still remains unknown.",
author = "Wassmann, {Claes S{\o}ndergaard} and Klitgaard, {Janne Kudsk}",
year = "2018",
language = "Dansk",
note = "18th International Symposium on Staphylococci and Staphylococcal infections, ISSSI2018 ; Conference date: 23-08-2018 Through 26-08-2018",
url = "http://isssi2018.org/",

}

Wassmann, CS & Klitgaard, JK 2018, 'Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues' 18th International Symposium on Staphylococci and Staphylococcal infections, København, Danmark, 23/08/2018 - 26/08/2018, .

Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues. / Wassmann, Claes Søndergaard; Klitgaard, Janne Kudsk.

2018. Abstract fra 18th International Symposium on Staphylococci and Staphylococcal infections, København, Danmark.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskning

TY - ABST

T1 - Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues

AU - Wassmann, Claes Søndergaard

AU - Klitgaard, Janne Kudsk

PY - 2018

Y1 - 2018

N2 - Development of resistance towards conventional antibiotics has become a huge problem worldwide. Infections which used to be easily treatable are now difficult to treat due to development of resistance. Therefore, we must turn to other approaches such as use of helper compounds. Helper compounds usually have no antibacterial properties themselves, however, when combined with antibiotics they are able to potentiate the effect of the antibiotic. In our group, we are searching for novel helper compounds to be used in combination with antibiotics to fight resistant bacteria.A potential helper compound is the cannabinoid cannabidiol (CBD) (Patent No. 17176612.4 - 1466). In our study, we have found through growth experiments that it is able to potentiate the effect of bacitracin against Methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria such as Listeria monocytogenes and Enterococcus faecalis. Currently, we are working to clarify the mechanism of action of CBD and how it potentiates the effect of bacitracin. Therefore, various molecular experiments have been conducted such as RNA-sequencing of treated bacteria and whole-genome sequencing of CBD resistant strains. These results have led to several interesting genes selected for further studies. In addition, treatment with CBD have also shown to disrupt the membrane potential leading us to look further into how CBD affects the bacterial membrane. Therefore, we are currently looking on how CBD affects membrane fatty acid composition, fluidity and surface charge. In conclusion, CBD is able to potentiate the effect of bacitracin towards MRSA, however, the mechanism of action still remains unknown.

AB - Development of resistance towards conventional antibiotics has become a huge problem worldwide. Infections which used to be easily treatable are now difficult to treat due to development of resistance. Therefore, we must turn to other approaches such as use of helper compounds. Helper compounds usually have no antibacterial properties themselves, however, when combined with antibiotics they are able to potentiate the effect of the antibiotic. In our group, we are searching for novel helper compounds to be used in combination with antibiotics to fight resistant bacteria.A potential helper compound is the cannabinoid cannabidiol (CBD) (Patent No. 17176612.4 - 1466). In our study, we have found through growth experiments that it is able to potentiate the effect of bacitracin against Methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria such as Listeria monocytogenes and Enterococcus faecalis. Currently, we are working to clarify the mechanism of action of CBD and how it potentiates the effect of bacitracin. Therefore, various molecular experiments have been conducted such as RNA-sequencing of treated bacteria and whole-genome sequencing of CBD resistant strains. These results have led to several interesting genes selected for further studies. In addition, treatment with CBD have also shown to disrupt the membrane potential leading us to look further into how CBD affects the bacterial membrane. Therefore, we are currently looking on how CBD affects membrane fatty acid composition, fluidity and surface charge. In conclusion, CBD is able to potentiate the effect of bacitracin towards MRSA, however, the mechanism of action still remains unknown.

M3 - Konferenceabstrakt til konference

ER -

Wassmann CS, Klitgaard JK. Characterization of Cannabidiol as a Helper Compound Against Resistant Staphylococcus aurues. 2018. Abstract fra 18th International Symposium on Staphylococci and Staphylococcal infections, København, Danmark.